Stock Fundamentals

Company Information

Company Name
Axsome Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US05464T1043
CIK: 0001579428
CUSIP: 05464T104
Currency: USD
Full Time Employees: 925
Phone: 212 332 3241
Fiscal Year End: December
IPO Date: Nov 19, 2015
Description:

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Address:

One World Trade Center, New York, NY, United States, 10007

Directors & Officers

Name Title Year Born
Dr. Herriot Tabuteau M.D. Founder, Chairman, CEO & President 1968
Mr. Nick Pizzie CPA, M.B.A. Chief Financial Officer 1975
Mr. Mark L. Jacobson M.A. Chief Operating Officer 1983
Mr. Hunter Murdock Esq. General Counsel & Secretary 1980
Mr. Ari Maizel Chief Commercial Officer 1979
Darren Opland Director of Corporate Communications NA

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 4.16M Dec 31, 2025 8.14% $0.01 -0.38%
BlackRock Inc 3.79M Sep 30, 2025 7.41% $0.01 -1.15%
Wellington Management Company LLP 1.22M Dec 31, 2025 2.39% $0.04 -8.46%
FMR Inc 1.18M Dec 31, 2025 2.31% $0.01 27.35%
Macquarie Group Ltd 1.08M Sep 30, 2025 2.12% $0.15 -4.68%
T. Rowe Price Associates, Inc. 1.04M Sep 30, 2025 2.03% $0.01 69.31%
Geode Capital Management, LLC 997.70K Sep 30, 2025 1.95% $0.01 0.83%
Amvescap Plc. 990.56K Sep 30, 2025 1.94% $0.02 73.31%
State Street Corp 942.96K Sep 30, 2025 1.84% $0.00 -1.62%
Deep Track Capital, LP 900.00K Sep 30, 2025 1.76% $3.05 12.31%
RTW INVESTMENTS, LLC 888.00K Dec 31, 2025 1.74% $1.62 -20.64%
Alethea Capital Management, LLC 670.88K Sep 30, 2025 1.31% $52.34 0.53%
Eventide Asset Management, LLC 571.23K Dec 31, 2025 1.12% $1.63 -23.47%
D. E. Shaw & Co LP 549.11K Dec 31, 2025 1.07% $0.06 85.33%
Orbimed Advisors, LLC 531.80K Sep 30, 2025 1.04% $1.52 24.28%
Partner Fund Management LP 530.33K Sep 30, 2025 1.04% $4.95 9.78%
JPMorgan Chase & Co 501.03K Sep 30, 2025 0.98% $0.00 166.89%
NORGES BANK 495.46K Dec 31, 2025 0.97% $0.01 5.79%
Assenagon Asset Management SA 467.98K Dec 31, 2025 0.91% $0.12 58.76%
Pictet Asset Manangement SA 436.06K Dec 31, 2025 0.85% $0.08 20.41%

Shares Statistics

Shares Outstanding: 51.15M
Shares Float: 43.23M
% Insiders: 1,586.00%
% Institutions: 7,594.10%
Short % Float: 6.34%

🏆 Top 10 Institutional Holders

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Group Inc 4.16M 8.14% ▼ 0.38% Dec 31, 2025
2 BlackRock Inc 3.79M 7.41% ▼ 1.15% Sep 30, 2025
3 Wellington Management Company LLP 1.22M 2.39% ▼ 8.46% Dec 31, 2025
4 FMR Inc 1.18M 2.31% ▲ 27.35% Dec 31, 2025
5 Macquarie Group Ltd 1.08M 2.12% ▼ 4.68% Sep 30, 2025
6 T. Rowe Price Associates, Inc. 1.04M 2.03% ▲ 69.31% Sep 30, 2025
7 Geode Capital Management, LLC 997.70K 1.95% ▲ 0.83% Sep 30, 2025
8 Amvescap Plc. 990.56K 1.94% ▲ 73.31% Sep 30, 2025
9 State Street Corp 942.96K 1.84% ▼ 1.62% Sep 30, 2025
10 Deep Track Capital, LP 900.00K 1.76% ▲ 12.31% Sep 30, 2025

Valuation Metrics

Enterprise Value: $8.28B
Trailing P/E: 0.00
Forward P/E: 333.33

Financial Highlights

Market Cap: $8.38B
EBITDA: $-160.17M
PEG Ratio: $0.00
Book Value: $1.74
Earnings/Share: $-3.69
Profit Margin: -28.69%
Operating Margin: -18.38%
ROA (TTM): -16.81%
ROE (TTM): -252.12%
Revenue (TTM): $638.50M
Revenue/Share (TTM): $12.84
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 65.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios (Yearly)

Financial Ratios (Quarterly)

Earnings History

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 1.55x 2.16x 0.87x -25.81x -1.13x
2024-12-31 2.11x 3.23x 0.90x -42.71x -0.67x
2023-12-31 3.63x 0.94x 0.68x -35.93x -0.80x
2022-12-31 2.54x 0.86x 0.67x -24.51x -0.54x
2021-12-31 3.75x 3.18x 0.82x -21.89x -0.40x
2020-12-31 7.85x 0.44x 0.39x -38.64x -0.49x
2019-12-31 9.00x -0.11x 0.19x -54.25x -0.30x
2018-12-31 1.41x 7.37x 0.94x -29.14x -0.21x
2017-12-31 2.90x 0.59x 0.53x -20.27x -0.36x
2016-12-31 5.30x 0.45x 0.44x -207.99x -0.35x
2015-12-31 18.63x 0.00x 0.05x -10.05x 0.00x
2014-12-31 2.82x -1.40x 2.15x -2.54x -1.63x
2013-12-31 0.51x -1.89x 1.97x -5.62x -2.08x

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 02, 2026 Herriot Tabuteau N/A Sale 32.41K $185.60 $6.02M
Jan 22, 2026 Nick Pizzie N/A Sale 12.00K $187.92 $2.26M
Jan 21, 2026 Ari Maizel N/A Sale 7.50K $184.44 $1.38M
Jan 07, 2026 Herriot Tabuteau N/A Sale 31.26K $170.38 $5.33M
Jan 06, 2026 Herriot Tabuteau N/A Sale 29.45K $172.33 $5.08M
Jan 05, 2026 Herriot Tabuteau N/A Sale 78.70K $171.28 $13.48M
Dec 31, 2025 Mark E Saad N/A Sale 37.58K $165.18 $6.21M
Dec 04, 2025 Herriot Tabuteau N/A Sale 10.56K $148.18 $1.56M
Dec 03, 2025 Herriot Tabuteau N/A Sale 20.16K $146.94 $2.96M
Dec 02, 2025 Herriot Tabuteau N/A Sale 49.25K $144.59 $7.12M
Nov 05, 2025 Herriot Tabuteau N/A Sale 21.78K $134.49 $2.93M
Nov 04, 2025 Herriot Tabuteau N/A Sale 50.46K $133.79 $6.75M
Nov 03, 2025 Herriot Tabuteau N/A Sale 91.71K $132.34 $12.14M
Oct 08, 2025 Herriot Tabuteau N/A Sale 12.77K $118.84 $1.52M
Oct 07, 2025 Herriot Tabuteau N/A Sale 13.39K $118.77 $1.59M
Oct 06, 2025 Herriot Tabuteau N/A Sale 19.22K $120.17 $2.31M
Sep 22, 2025 Mark L Jacobson N/A Sale 10.00K $115.96 $1.16M
Sep 16, 2025 Herriot Tabuteau N/A Sale 19.72K $114.19 $2.25M
Sep 16, 2025 Mark L Jacobson N/A Sale 45.78K $114.48 $5.24M
Sep 15, 2025 Herriot Tabuteau N/A Sale 15.25K $117.37 $1.79M

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AXSM.US!